Compare Incyte Corporation (INCY) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs VF Corp — how do they compare? Incyte Corporation trades at $120.85 (market cap $24.54B), while VF Corp trades at $14.61 (market cap $5.81B). The key difference: Incyte Corporation is far larger — about 4.2× VF Corp's market cap, and VF Corp pays a 2.44% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | VFC | |
|---|---|---|
Market Cap | $24.54B | $5.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $21.55 |
52-Week Low | $81.61 | $12.21 |
Enterprise Value | $20.04B | $10.09B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
VFC trades at $14.90, down 0.6% on the day, near the low end of analyst targets. Technical indicators are bearish, with mixed recent earnings showing a Q4 beat but Q1 and Q2 misses. Revenue has declined from $11.8B in 2022 to $9.5B in 2025, with net losses in 2024 and 2025, though 2026 projects a return to profitability. The company faces brand-specific headwinds, particularly with Vans, while maintaining a reasonable P/S ratio of 0.62.
The outlook is cautious. Deleveraging progress and a raised 2027 revenue outlook offer some optimism, but persistent Vans weakness and macro pressures pose significant risks. Analyst consensus is Hold, with a $17.44 price target suggesting limited upside from current levels amid ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
